News Channels

17 Nov 2017 Alnylam Initiates Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Patisiran for the Treatment of Hereditary ATTR (hATTR) Amyloidosis
17 Nov 2017 bluebird bio Announces First Patient Treated in Northstar-3 (HGB-212), Phase 3 Study of LentiGlobin™ in Patients with Transfusion-Dependent β-Thalassemia (TDT) and β0/β0 Genotype
17 Nov 2017 Cue Biopharma Announces Strategic Research Collaboration and License Agreement with Merck
17 Nov 2017 Celgene Corporation and bluebird bio Announce bb2121 Anti-BCMA CAR-T Cell Therapy Has Been Granted Breakthrough Therapy Designation from FDA and Prime Eligibility from EMA for Relapsed and Refractory Multiple Myeloma
17 Nov 2017 Pfizer Receives FDA Approval for SUTENT® (sunitinib malate) as First and Only Adjuvant Treatment for Adult Patients at High Risk of Recurrent Renal Cell Carcinoma
17 Nov 2017 Seattle Children's Opens First CAR T-Cell Immunotherapy Trial in the U.S. for Children and Young Adults With Leukemia that Targets CD22 and CD19 Proteins Simultaneously
17 Nov 2017 Evelo Biosciences and Mayo Clinic Collaborate to Advance Monoclonal Microbials for the Treatment of Inflammatory and Neuroinflammatory Diseases
17 Nov 2017 Agios Presents Updated Phase 1 Data from Dose Expansion Cohort of Ivosidenib (AG-120) in Patients with IDH1 Mutant Positive Glioma
17 Nov 2017 Celldex Therapeutics Initiates Phase 2 Combination Study of CDX-3379 and Cetuximab in Head and Neck Squamous Cell Carcinoma
17 Nov 2017 Medicenna Presents Updates on Phase 2b Clinical Trial of MDNA55 at the Annual Meeting of the Society of Neuro-Oncology
17 Nov 2017 Oncolytics Biotech® Inc. and Adlai Nortye Enter into USD $86.6 Million Regional Licensing Agreement for REOLYSIN®
17 Nov 2017 Ionis Pharmaceuticals Licenses Second Orally Delivered Antisense Drug to Janssen
17 Nov 2017 FDA Approves Genentech’s Gazyva for Previously Untreated Advanced Follicular Lymphoma
17 Nov 2017 Chugai’s HEMLIBRA® Receives the World’s First Regulatory Approval from FDA for Hemophilia A with Inhibitors
16 Nov 2017 Ascentage Pharma Announces U.S. FDA Acceptance of IND Application for Clinical Study of Novel IAP Inhibitor APG-1387 to Treat Advanced Solid Tumors and Blood Cancers
16 Nov 2017 Biohaven Completes Enrollment In The First Of Two Pivotal Phase 3 Clinical Trials Of Rimegepant, A Second Generation Oral CGRP-Receptor Antagonist, For The Acute Treatment Of Migraine
16 Nov 2017 Sobi™ - First Patient Randomised in a Phase 3 Study Evaluating Safety and Efficacy of Anakinra in the Treatment of Still's Disease
16 Nov 2017 BioCanCell Announces Updated Results from the Phase 2 Clinical Trial of BC-819 and BCG in Patients with Bladder Cancer
16 Nov 2017 Trelegy Ellipta Once-Daily Single Inhaler Triple Therapy Gains Marketing Authorisation in Europe for the Treatment of COPD
15 Nov 2017 Moderna Announces First-in-Human Dosing for Phase 1 Study (KEYNOTE-603) of mRNA-4157, a Personalized Cancer Vaccine, for the Treatment of Solid Tumors

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing